Colorectal Cancer Trial, Recruiting NCT06880055 Sponsor: Guardant Health, Inc. Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT06880055
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 45 to 81 years old at the time of signing the consent form
  • People who are planning to have a standard Shield test (a type of bowel cancer screening test)
  • People considered by their doctor or healthcare provider to be at average risk for bowel cancer — meaning they have no symptoms of bowel cancer and no known factors that increase their risk
  • People who are willing to follow the study procedures and attend the related standard medical appointments

Who may not be able to join:

  • People having a colonoscopy because they are experiencing symptoms
  • People with a personal history of bowel cancer, adenomas (a type of bowel polyp), or related cancers
  • People with a family history of bowel cancer, meaning at least one parent, sibling, or child has been diagnosed with bowel cancer at any age
  • People who have had a positive result on another bowel cancer screening test recently — within the last 12 months for a stool blood test (FOBT or FIT), or within the last 36 months for a FIT-DNA test
  • People with a personal history of high-risk bowel conditions, such as Inflammatory Bowel Disease (including ulcerative colitis and Crohn's disease), Familial Adenomatous Polyposis, or inherited cancer syndromes such as Lynch Syndrome or Peutz-Jeghers Syndrome, among others (confirm full list with trial site)
  • People who have had a positive Shield test result within the past 3 years
  • People with a history of any cancer — except those who had a type of skin cancer (squamous cell carcinoma) surgically removed at least 12 months before signing the consent form
  • People currently taking certain medications used to treat cancer or to modify immune diseases (DMARDs)
  • People who have had a major physical event in the 30 days before signing the consent form, such as surgery, a serious injury, an organ transplant, or a blood transfusion
  • People with a medical condition that the trial investigator believes makes participation unsuitable
  • People who have received, or may receive, an experimental medication as part of another clinical study within 30 days before signing the consent form, or between signing the consent form and having their colonoscopy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 415-307-2774

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Guardant Health, Inc.
Registry
ClinicalTrials.gov
Start date
14 July 2025
Est. completion
1 September 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Performance measures of the Shield test will be assessed for the second testing interval

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov